Clinical Trials Logo

Coronary Artery Disease (CAD) clinical trials

View clinical trials related to Coronary Artery Disease (CAD).

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06052319 Recruiting - Clinical trials for Coronary Artery Disease (CAD)

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

IPACE-CVD
Start date: November 29, 2023
Phase:
Study type: Observational

The purpose of this study is to assess the engagement and usefulness of Care4Today® Connect CAD-PAD digital platform in participants with coronary artery disease or peripheral artery disease (CAD or PAD).

NCT ID: NCT05698732 Recruiting - Clinical trials for Ischemic Heart Disease

Coroflex® ISAR NEO PMCF Study

rEPIC07
Start date: August 4, 2023
Phase:
Study type: Observational

International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Coroflex® ISAR NEO coronary stent system sirolimus eluting stent.

NCT ID: NCT05617599 Recruiting - Clinical trials for Ischemic Heart Disease

SUPRAFLEX CRUZ PMCF Study ( rEpic05 )

Multiflex
Start date: May 10, 2023
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).

NCT ID: NCT05516446 Recruiting - Clinical trials for Coronary Artery Disease (CAD)

Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent

DEBATE
Start date: August 25, 2021
Phase: N/A
Study type: Interventional

Randomized, open-label, single-center, non-inferiority clinical trial to compare late lumen loss (LLL) at 12 months in Tunisian population undergoing coronary percutaneous intervention between Drug Eluting Balloon treated group and Everolimus platinum chrome stent treated group.

NCT ID: NCT05292118 Recruiting - Clinical trials for Ischemic Heart Disease

Navitian PMCF Study ( rEPIC04C )

rEPIC04C
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Navitian to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Navitian.

NCT ID: NCT05292092 Recruiting - Clinical trials for Ischemic Heart Disease

Essential Pro PMCF Study ( rEPIC04E )

rEPIC04E
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.

NCT ID: NCT05292079 Recruiting - Clinical trials for Ischemic Heart Disease

CAPTURER PMCF Study ( rEPIC04D )

rEPIC04D
Start date: September 29, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of CAPTURER to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with CAPTURER .

NCT ID: NCT05292014 Recruiting - Clinical trials for Ischemic Heart Disease

ANGIOLITE PMCF Study ( rEPIC04F )

rEPIC04F
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Angiolite sirolimus eluting stent to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Angiolite sirolimus eluting stent.

NCT ID: NCT04725539 Recruiting - Clinical trials for Coronary Artery Disease (CAD)

Hypoxia Pre-conditioning and Mountain Sport

Hyx-PRE-Spo
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Mountain sport activities as for example hiking or skiing may involve the risk of adverse health events especially in older people not accustomed to the specific mountain sport at altitude or people with pre-existing health issues. Increased activation of the sympathetic nervous system and abrupt changes in heart rate and blood pressure are thought to trigger these adverse effects. Preventive measures include regular physical activity (i.e. training) and adequate medical treatment. Hypoxia pre-adaptation (e.g., pre-adapt one night at moderate altitude) and pre-conditioning (e.g., intermittent hypoxia (IH) training), which was shown to lead to some favorable sympathetic nervous system, ventilatory and metabolic adaptations and additionally exerts anti-inflammatory action, could be hypothesized of being a further preventive measure. The aim of this research project is to investigate whether intermittent hypoxia pre-conditioning or sleeping one night at altitude (i.e., current recommendation before practicing mountain leisure sports in the elderly) is able to increase oxygen saturation during passive hypoxia exposure and during simulated hiking and skiing at altitude. Additionally, it is aimed to investigate whether such procedure reduces the physiological responses (i.e., heart rate, its variability and blood pressure (including baroreflex sensitivity) responses as well as metabolic, ventilatory, inflammatory and redox responses) during these activities.

NCT ID: NCT02624297 Recruiting - Clinical trials for Coronary Artery Disease (CAD)

Chemoreflex Control of Sympathetic Activity in Patients With Coronary Artery Disease

Start date: January 2014
Phase: N/A
Study type: Interventional

The investigators hypothesize that chemoreflex response of muscle sympathetic nerve activity (MSNA) during hypoxia and hypercapnia will be increased in coronary artery disease (CAD) patients and that the presence of obstructive sleep apnea (OSA) will potentiate these responses. And, that the exercise training would decrease the chemoreflex response of MSNA in these patients.